In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
We have
197
projects in our pipeline
